BEROMUN

This brand name is authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Lithuania, Poland, Spain, UK.

Active ingredients

The drug BEROMUN contains one active pharmaceutical ingredient (API):

1	Tasonermin UNII 23CA79S88F - TASONERMIN
	Tasonermin is cytotoxic or cytostatic in vitro for a variety of tumour cell lines of different histogenesis. Tasonermin affects the morphology and reduces proliferation of endothelial cells. Also, it has profound effects on cellular components of the immune system.
	Read more about Tasonermin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BEROMUN Powder for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L03AX11	Tasonermin	L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AX Other immunostimulants
Discover more medicines within L03AX11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1204861
ES	Centro de información online de medicamentos de la AEMPS	99097001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	598423
FR	Base de données publique des médicaments	69328782
GB	Medicines & Healthcare Products Regulatory Agency	346078
LT	Valstybinė vaistų kontrolės tarnyba	1027709
PL	Rejestru Produktów Leczniczych	100012572